Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 2
1981 2
1982 4
1983 3
1984 4
1985 6
1986 1
1987 16
1988 18
1989 23
1990 31
1991 29
1992 42
1993 71
1994 88
1995 104
1996 136
1997 125
1998 140
1999 143
2000 139
2001 151
2002 183
2003 201
2004 288
2005 293
2006 303
2007 391
2008 502
2009 623
2010 747
2011 896
2012 1069
2013 1195
2014 1416
2015 1497
2016 1537
2017 1623
2018 1715
2019 1844
2020 1926
2021 2232
2022 2292
2023 2517
2024 3963
2025 6177
2026 4892

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,945 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Risk of Psoriatic Arthritis in Type 2 Diabetes: An Emulated Target Trial of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists.
Yen FS, Wang SI, Hwu CM, Chen KY, Hsu CC, Wei JC. Yen FS, et al. Drug Des Devel Ther. 2026 Jul 15;20:614222. doi: 10.2147/DDDT.S614222. eCollection 2026. Drug Des Devel Ther. 2026. PMID: 42473649 Free PMC article.
OBJECTIVE: We conducted this emulated target trial to compare the risk of incident PsA among patients with T2DM treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus those treated with glucagon-like peptide-1 receptor agonists (GLP …
OBJECTIVE: We conducted this emulated target trial to compare the risk of incident PsA among patients with T2DM treated with sodium-glucose …
Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.
Timmons JG, Ghanim H, Boyle JG, Greenlaw N, Chaudhuri A, Batra MA, Lindsay RS, Jolly L, Bonner C, McConnachie A, Petrie JR, Dandona P. Timmons JG, et al. Diabetes Obes Metab. 2026 Jul 19. doi: 10.1111/dom.71076. Online ahead of print. Diabetes Obes Metab. 2026. PMID: 42473259
We designed the first Phase 3 clinical trial to assess the efficacy and safety of adding a Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) and a Sodium-Glucose Co-transporter (SGLT2) Inhibitor to insulin therapy in overweight and obese adults with T …
We designed the first Phase 3 clinical trial to assess the efficacy and safety of adding a Glucagon-Like Peptide 1 …
Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulation.
Li Y, Ye D, Fu C, Huang X, Ma Q, Zhang F, Chen G, Song P, Kong C, Wu J, Wu H, Qiao J, Yang J. Li Y, et al. Gut Microbes. 2026 Dec 31;18(1):2687937. doi: 10.1080/19490976.2026.2687937. Epub 2026 Jul 19. Gut Microbes. 2026. PMID: 42473065
In this study, we found that the metabolic supernatant of AKK promoted GLP-1 and GIP secretion in STC-1 cells. Metabolomic profiling identified 54 small molecules in the AKK supernatant, among which a bioactive hexapeptide, LKLKLL, was identified. ...Together, these …
In this study, we found that the metabolic supernatant of AKK promoted GLP-1 and GIP secretion in STC-1 cells. Metabolomic pro …
Probiotic supplementation as a strategy to counteract chronic hypoxia-related damages.
Grasselli FM, Bonfili L, Cuccioloni M, Cecarini V, Angeletti M, Marazzato M, Sonsini G, Ubaldi M, Biagini L, Galosi L, Rossi G, Eleuteri AM. Grasselli FM, et al. Brain Behav Immun. 2026 Jul 19:106920. doi: 10.1016/j.bbi.2026.106920. Online ahead of print. Brain Behav Immun. 2026. PMID: 42472610
Probiotics also normalized plasma gut hormones (glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and leptin), enhanced ileal tight junction proteins (zonulin-1, occludin and claudin) in Ileal tissue, co …
Probiotics also normalized plasma gut hormones (glucagon-like peptide-1 (GLP-1), glucose-dependent …
Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lv R, Peng L, Xu Y, Du X, Liu H, Wu H, Zhang Y, Li Q, Jiao X, Piao C, Yang S, Lin X, Li L, Ye Z, Chen J; SOLID-DKD Investigator Groupl; SOLID-DKD Investigator Group. Lv R, et al. EClinicalMedicine. 2026 Jul 9;97:104045. doi: 10.1016/j.eclinm.2026.104045. eCollection 2026 Jul. EClinicalMedicine. 2026. PMID: 42472282 Free PMC article.
BACKGROUND: The efficacy of non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonists in diabetic kidney disease remains uncertain, particularly as add-on therapy to contemporary high-intensity treatments. We assessed H …
BACKGROUND: The efficacy of non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor ag …
Peptide-functionalized nanoemulsions with exendin-4 as a model ligand.
Holler N, Gesslbauer B, Tam-Amersdorfer C, Letofsky-Papst I, Mayrhofer C, Andreae F, Zimmer A. Holler N, et al. Int J Pharm X. 2026 Jul 2;12:100598. doi: 10.1016/j.ijpx.2026.100598. eCollection 2026 Dec. Int J Pharm X. 2026. PMID: 42472074 Free PMC article.
Glucagon-like peptide-1 receptor (GLP-1R) agonists are increasingly explored for the treatment of obesity and metabolic disorders, yet the biological consequences of presenting these ligands on the surface of lipid-based nanocarriers remain insufficien …
Glucagon-like peptide-1 receptor (GLP-1R) agonists are increasingly explored for the treatment of obesity and me …
Association between body mass index reduction and epicardial adipose tissue changes across pharmacological and lifestyle interventions: a multilevel meta-regression analysis.
Mączyńska A, Olbryś P, Smoliński M, Rosa M, Kacperska M, Froń M, Leśniewski P, Łuniewska O, Sander A, Mączewski M, Czerwińska H, Paterek A, Mączewski M. Mączyńska A, et al. Cardiovasc Diabetol. 2026 Jul 19. doi: 10.1186/s12933-026-03299-6. Online ahead of print. Cardiovasc Diabetol. 2026. PMID: 42471652 Free article. Review.
Larger observed reductions in EAT were seen with dietary interventions, GLP-1 receptor agonists, and bariatric surgery. In descriptive residual analyses, dietary interventions and GLP-1 receptor agonists demonstrated greater-than-predicted reductions i …
Larger observed reductions in EAT were seen with dietary interventions, GLP-1 receptor agonists, and bariatric surgery. In des …
Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery.
Nguefang GL, Boateng S, Issaka Y, Landa EL, Gyabaah S, Konlack JG, Njei B. Nguefang GL, et al. Obes Surg. 2026 Jul 18. doi: 10.1007/s11695-026-08864-2. Online ahead of print. Obes Surg. 2026. PMID: 42471527
Adults with BMI > 30 were classified into GLP-1 RA after MBS, GLP-1 before MBS, and MBS-only cohorts. We performed 1:1 propensity score matching to compare each GLP-1 RA strategy to MBS only. ...GLP-1 RA after MBS reduced …
Adults with BMI > 30 were classified into GLP-1 RA after MBS, GLP-1 before MBS, and MBS-only cohorts. We perf …
Can glucagon-like peptide-1 receptor agonists affect outcomes after spine surgery? A systematic review and meta-analysis.
Muthu S, Viswanathan VK, Kolarpatti Ponnusamy DV, Samuel MS, Rajappan Chandra SK, Sharun K, Hiatt L, Rajaram Manoharan SR, Theiss S. Muthu S, et al. Eur Spine J. 2026 Jul 18. doi: 10.1007/s00586-026-10205-x. Online ahead of print. Eur Spine J. 2026. PMID: 42471496 Review.
PURPOSE: To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and perioperative, postoperative and fusion-related outcomes following spine surgery. ...
PURPOSE: To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and perioper …
36,945 results
You have reached the last available page of results. Please see the User Guide for more information.